Loading
A phase 3 trial of Datopotamab deruxtecan, Osimertinib, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06417814 by AstraZeneca, with 744 participants planned, started 2024-10-04 and due to reach its primary completion in 2026-09-30. Interventions recorded: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, AstraZeneca.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-cell lung cancer.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin.
Shares Datopotamab deruxtecan, Osimertinib, AstraZeneca, Small-cell lung cancer.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.